eGenesis picks Daniel Leblanc as new Chief Manufacturing and Supply Officer. The company's lead product is a genetically engineered porcine kidney for human patients with kidney failure. October 22, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. eGenesis, a biotechnology company developing human-compatible engineered organs, appointed Daniel Leblanc Chief Manufacturing and Supply Officer. What eGenesis does. The company, headquartered in Cambridge, Mass., aims to develop these organs to address what it calls a global organ shortage. Currently, eGenesis is advancing its lead product, EGEN-2784, a genetically engineered porcine kidney for patients with kidney failure. Leblanc preceded his eGenesis appointment by serving as Chief Technology Officer at Ensoma. He previously held senior leadership positions at Flexion Therapeutics. The most recent of these was Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) Operations. Earlier in his career, Leblanc held CMC and manufacturing leadership positions at Merck Serono and Alkermes. Overall, he brings more than 25 years of global biopharmaceutical industry experience to his new position and company. Manufacturing and Supply expertise needed. "Dan brings extensive expertise in manufacturing and operational strategy for innovative therapies," eGenesis President and CEO Mike Curtis, PhD, said. "His leadership will be instrumental as we advance our clinical programs and prepare for future commercialization... We [will] continue to build the infrastructure necessary to bring genetically engineered organs to patients in need." "eGenesis is at the forefront of the treatment of organ failure," Leblanc said. "I am excited to join the company at such an important stage in its development. The progress eGenesis has made in advancing genetically engineered organs into the clinic underscores the tremendous potential of this technology. I look forward to working with the team to further strengthen manufacturing capabilities, establish scalable operations, and support [their] mission." To date, the United States FDA has cleared eGenesis to conduct clinical studies across its kidney and liver programs. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Natco Pharma raises eGenesis investment to $16.7 million, backs gene-edited organ research. Natco Pharma has raised its investment in US biotech eGenesis to $16.7 million from $14 million, as it backs research aimed at using gene-edited pig organs for human transplants. By Megha Rani September 28, 2026, 4:33:27 PM IST (Updated) Natco Pharma has increased its proposed investment in US-based biotechnology company eGenesis Inc. to $16.7 million from the previously disclosed $14 million, the company said in an exchange filing on Monday, September 28. The investment will be made through Natco Pharma's wholly owned subsidiaries Natco Pharma (Canada) Inc. and Natco Pharma USA LLC through convertible promissory notes carrying an interest rate of 8% compounded annually. Natco Pharma (Canada) will invest $13.7 million, while Natco Pharma USA will invest another $3 million. The investment is expected to be completed by October 31, 2026. The latest investment is an update to Natco Pharma's disclosure on August 25. The company also said there has been a change in the subsidiaries participating in the investment. Following the proposed investment, Natco Pharma's total investment in eGenesis will rise to $24.7 million, including the $8 million it invested in the US biotech in 2024. What does eGenesis do? eGenesis is developing technology that could potentially help address the shortage of human organs available for transplantation. The company uses gene editing to modify pig organs so they can potentially be transplanted into humans while reducing the risk of rejection and viral transmission. eGenesis is currently developing programmes involving kidney transplantation, acute liver failure and heart transplantation. The company made headlines in March 2024 after conducting the world's first pig-kidney transplant in a living patient. The transplant was authorised by the US Food and Drug Administration under its Expanded Access pathway. Two additional patients subsequently received pig-kidney transplants, Natco Pharma said. eGenesis is currently a clinical-stage, pre-revenue company and is conducting clinical trials involving pig-kidney transplantation in humans and pig-liver perfusion. For Natco Pharma, the investment is aimed at backing new-age therapeutic programmes addressing critical unmet medical needs, according to the company's disclosure.